HK inno.N Receives Marketing Authorization for New Influenza Treatment 'Peramix Injection'
Domestic pharmaceutical company HK inno.N has received approval from the Ministry of Food and Drug Safety for a new influenza treatment. On the 24th, HK inno.N announced that it had obtained marketing authorization for 'Peramix Injection,' a new influenza treatment in the form of an IV bag.
Unlike existing injection forms, the newly approved 'Peramix Injection' was developed as an IV bag formulation, enhancing convenience in medical settings. This product is a pharmaceutical used for the treatment of influenza virus infections and is expected to provide patients with a new therapeutic option.
With the recent recurrence of influenza outbreaks, the importance of treatments is growing. In particular, if this new product is supplied to the market in time for the winter flu season, it is expected to be of great help to both medical staff and patients.
HK inno.N plans to strengthen its competitiveness in the influenza treatment market following this approval. The company stated that it will continue to contribute to the improvement of public health by developing a variety of pharmaceuticals.
Industry attention is focused on what changes this marketing authorization will bring to the domestic influenza treatment market. All eyes are on how the new treatment will be utilized in actual medical practice.